- Home
- ZNTL
as of 03-02-2026 3:54pm EST
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 156.7M | IPO Year: | 2020 |
| Target Price: | $6.60 | AVG Volume (30 days): | 623.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | 47.87 |
| 52 Week Low/High: | $1.01 - $3.95 | Next Earning Date: | N/A |
| Revenue: | $67,425,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.67 | Index: | N/A |
| Free Cash Flow: | -171081000.0 | FCF Growth: | N/A |
AI-Powered ZNTL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Zentalis Pharmaceuticals Inc. (ZNTL)
PAO and PFO
Avg Cost/Share
$2.42
Shares
6,894
Total Value
$16,699.34
Owned After
146,506
SEC Form 4
PAO and PFO
Avg Cost/Share
$2.39
Shares
3,379
Total Value
$8,085.61
Owned After
146,506
SEC Form 4
CEO & President
Avg Cost/Share
$2.39
Shares
889
Total Value
$2,127.29
Owned After
79,133
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$2.39
Shares
335
Total Value
$801.62
Owned After
33,332
SEC Form 4
PAO and PFO
Avg Cost/Share
$2.43
Shares
29,951
Total Value
$72,771.94
Owned After
146,506
SEC Form 4
CEO & President
Avg Cost/Share
$2.43
Shares
7,866
Total Value
$19,112.02
Owned After
79,133
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$2.43
Shares
2,962
Total Value
$7,196.77
Owned After
33,332
SEC Form 4
PAO and PFO
Avg Cost/Share
$2.52
Shares
556
Total Value
$1,398.34
Owned After
146,506
SEC Form 4
PAO and PFO
Avg Cost/Share
$2.55
Shares
2,540
Total Value
$6,477.00
Owned After
146,506
SEC Form 4
10% Owner
Avg Cost/Share
$1.20
Shares
6,459,973
Total Value
$7,751,967.60
Owned After
13,509,973
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | ZNTL | PAO and PFO | Feb 10, 2026 | Sell | $2.42 | 6,894 | $16,699.34 | 146,506 | |
| Vultaggio Vincent | ZNTL | PAO and PFO | Feb 9, 2026 | Sell | $2.39 | 3,379 | $8,085.61 | 146,506 | |
| EASTLAND JULIA MARIE | ZNTL | CEO & President | Feb 9, 2026 | Sell | $2.39 | 889 | $2,127.29 | 79,133 | |
| Bruns Ingmar | ZNTL | Chief Medical Officer | Feb 9, 2026 | Sell | $2.39 | 335 | $801.62 | 33,332 | |
| Vultaggio Vincent | ZNTL | PAO and PFO | Feb 6, 2026 | Sell | $2.43 | 29,951 | $72,771.94 | 146,506 | |
| EASTLAND JULIA MARIE | ZNTL | CEO & President | Feb 6, 2026 | Sell | $2.43 | 7,866 | $19,112.02 | 79,133 | |
| Bruns Ingmar | ZNTL | Chief Medical Officer | Feb 6, 2026 | Sell | $2.43 | 2,962 | $7,196.77 | 33,332 | |
| Vultaggio Vincent | ZNTL | PAO and PFO | Feb 3, 2026 | Sell | $2.52 | 556 | $1,398.34 | 146,506 | |
| Vultaggio Vincent | ZNTL | PAO and PFO | Feb 2, 2026 | Sell | $2.55 | 2,540 | $6,477.00 | 146,506 | |
| WALTERS GROUP | ZNTL | 10% Owner | Dec 31, 2025 | Buy | $1.20 | 6,459,973 | $7,751,967.60 | 13,509,973 |
Compare ZNTL vs Leading Stocks
See how ZNTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZNTL Zentalis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.